PPARG and type 2 diabetes mellitus: Rosiglitazone is a PPAR-γ (peroxisome proliferator-activated receptor-gamma) agonist that has been shown to improve insulin sensitivity, resulting in improved glycaemic control in people with type 2 diabetes [12-14].